Taeho Greg Rhee, PhD, FACE

Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut

JCP
SSRI, SNRI, or Other Antidepressant Use Not Associated With Differential Outcomes in Ketamine or Esketamine Treatment
Brief Report

April 27, 2026

No group differences were seen between concurrent oral antidepressant class and clinical outcomes in patients treated with IV ketamine or IN esketamine.
, , , et al
JCP
Innovation in Psychiatric Drug Development: A Quantitative Analysis of FDA-Approved Psychiatric Drugs, 2012–2024
Original Research

January 12, 2026

Innovation in psychiatric drug development in the past 13 years was limited, with most new drugs representing incremental advances rather than groundbreaking innovations.
, , , et al
JCP
Ketamine and Esketamine: Is There a Meaningful Clinical Difference?
Commentary

September 22, 2025

The authors comment on a recent chart review by Meisner and colleagues.
,
JCP
Comparing the Cognitive Effects of Repeated IV Ketamine and ECT in Patients with Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D Trial
Original Research

September 3, 2025

Patients treated with ketamine demonstrated superior cognitive functioning compared with those treated with ECT following a 3-week treatment course. No differences between treatments were observed among responders in at...
, , , et al
JCP
Global Population-Based Study on the Association Between Ketamine and Esketamine with Suicidality Using WHO VigiBase
Original Research

July 7, 2025

The results do not provide causal evidence of worsening suicidality in persons receiving esketamine/ketamine; mixed results of increased and decreased risk of suicidality were reported with both agents.
, , , et al
JCP
ECT for Psychotic vs Nonpsychotic Depression
Original Research

January 29, 2025

Patients with major depression with psychotic features had higher response rates to ECT than those without psychotic features and similar rates of adverse cognitive effects. After adjustment for confounders,...
, , , et al
JCP
Ketamine vs ECT in the Management of Treatment-Resistant Depression: Do We Need More Data?
Brief Report

January 27, 2025

Data suggest the difference between ketamine and ECT in efficacy for treatment-resistant depression may be smaller than previously thought.
, , , et al
JCP
How to Value a Life Without Limits: Quantifying Suffering With Quality-Adjusted Life Years in Social Anxiety Disorder
Commentary

May 27, 2024

The authors discuss a recent intriguing study published in JCP by Patel et al.
,
JCP
Suicide Attempts and Health-Related Quality of Life
Original Research

February 27, 2023

People with recent suicide attempts have much lower mental health–related QOL than those with no attempt or an attempt in the distant past. Psychiatric and substance use comorbidities explain...
, ,
JCP
Effects of ECT in Comorbid Depression and Dementia
Original Research

January 25, 2023

Limited data suggest a role for electroconvulsive therapy (ECT) in treating behavioral and psychological symptoms of dementia. Using a larger sample size than in previous reports, this study examined...
, , , et al
JCP
Social Support and Suicidal Thoughts and Behaviors
Original Research

December 5, 2022

Greater diversity of social networks was more strongly associated with lower risks of suicidal thoughts and behaviors than perceived strength of social support.
, , , et al
JCP
Increased Admissions for Substance Use Disorder Among Older Adults, 2000–2017
Original Research

March 28, 2022

From 2000 to 2017, the number of older adults admitted for substance use disorder treatment increased by 203.7%, as compared to 13.0% in younger adults. This study looks at...
, ,

Insightful. Evidence-based. Human-centered.

Listen to the JCP Podcast Now
Figure: Digital illustration shows a human head with neural connections and podcast title over a dark blue patterned background.

Subscribe to read
more articles

Subscribe